Company intelligence
Ipsen
About Ipsen
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries. For more information, visit ipsen.com. Pauta exclusiva para México: Clave de Autorización COFEPRIS: 243300201B1962 CONSULTE A SU MÉDICO.
Verified activity
Signals from Ipsen
9 published signals
Presence & Recognition
Ipsen welcomed employees back to their hubs in the UK, France, and the US during September.
Reported by Ipsen
Presence & Recognition
Ipsen colleagues are participating at the Imagine for Margo - Children without Cancer charity race
Reported by Laura Santi
Presence & Recognition
Ipsen's Czech and Slovak team participated in the 23rd pétanque tournament organized by the Chamber of Commerce Franco-Tchèque/Francouzsko-Česká Obchodní Komora as part of the Chamber's 30th anniversary celebrations.
Reported by Matteo Medici
People
Ipsen employs Jon T. who helps find the next generation of cancer medicines through an extended access programme.
Reported by Ipsen
People
Ipsen is hiring a Senior Manager, Medical Communications & Publications for Michelle Ciambella.
Reported by Michael Hurynowicz
People
Ipsen is hiring talent management leaders for its Lifesciences division.
Reported by Alessandra Benevolo
People
Ipsen appointed Alison O'Malley as the new Northeast Field Access Director for Rare Disease, Liver with IPSEN Biopharmaceuticals.
Reported by Alison O'Malley
Presence & Recognition
Ipsen is participating in the Oncology & Immunology Innovation Partnering & Licensing Summit on Deal Trends Following Best-in-Class Opportunities in Oncology
Reported by Anu Connor
Presence & Recognition
Ipsen hosted a Cycle Meeting with Czech and Slovak teams to look back on achievements in the first half of 2026, welcome new colleagues, and align on future goals.
Reported by Matteo Medici